TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05329493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling digit device application
Description: Cooling digit device will be applied on subject's right hand ( fifth finger).
Study: NCT05813171

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Allicor
Description: Participants will take Allicor capsules in addition to standard treatment for a year.
Study: NCT05001945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLS-101 (Part I)
Description: MLS-101 tablet(s) by mouth once or twice daily.
Study: NCT04696029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine
Description: DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C).
Study: NCT05761756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Deprivation
Description: 24 hours sleep deprivation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Oral administration of caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Oral administration of methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Description: Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
Study: NCT05001945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLS-101 (Part I)
Description: MLS-101 tablet(s) by mouth once or twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLS-101 (Part I)
Description: MLS-101 tablet(s) by mouth once or twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part I)
Description: Placebo tablet(s) by mouth once or twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part II)
Description: Placebo tablet(s) by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLS-101 (Part II)
Description: MLS-101 tablet(s) by mouth once daily.
Study: NCT06072105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Description: Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary, personalized symptomatic treatment
Description: Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, personalized symptomatic treatment
Description: Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
Study: NCT05469802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Inactivated Zika Virus Vaccine (PIZV)
Description: PIZV vaccine with aluminium hydroxide adjuvant IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline (0.9% NaCl) IM injection.
Study: NCT05437991

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Independent morphological quantifications by echo-doppler using ECST method
Description: The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
Study: NCT06456840

Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASOUND
Description: Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.

Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASOUND
Description: Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.

Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASOUND
Description: Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.

Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASOUND
Description: Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.
Study: NCT05309525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum-Aaes
Description: subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum-Aaes
Description: subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
Study: NCT05813171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take the placebo capsules in addition to standard treatment for a year.
Study: NCT05309525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum-Aaes
Description: subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysteda 650 MG Oral Tablet
Description: Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysteda 650 MG Oral Tablet
Description: Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysteda 650 MG Oral Tablet
Description: Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
Study: NCT06005220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SBD121
Description: Medical Food

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05274633

Intervention type: DRUG
Intervention: Ravulizumab
Description: Participants will be observed for 52 weeks after the start of ravulizumab.
Study: NCT06323174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Study: NCT06361537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCTA-C1-INH
Description: OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL/kg BW 0.9% sodium chloride injection
Study: NCT05985135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy
Description: Needle muscle biopsy of the outer thigh muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label

Intervention type: OTHER
Group type: OTHER
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jell-O with Amino acids
Description: An amino acid mixture containing 13C6 Lysine isotope label

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Intravenous form of sugar
Study: NCT06641908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3554
Description: M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
Study: NCT04234022

Intervention type: DRUG
Intervention: Zn-DDC
Description: Zn-DDC added to myeloma samples for culturing
Study: NCT05714982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label with text health warning
Description: Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label with pictorial health warning
Description: Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
Study: NCT05207046

Intervention type: OTHER
Intervention: Mechanical Ventilation
Description: Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.

Intervention type: OTHER
Intervention: Mechanical Ventilation
Description: Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
Study: NCT06554353

Intervention type: DEVICE
Intervention: Oscillometer
Description: The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
Study: NCT04187326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Microexpression Training
Description: The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
Study: NCT06482554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumateperone 42 mg
Description: Standard treatment with lumateperone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 2 mg
Description: Standard treatment with other antipsychotic drugs
Study: NCT05714982

Intervention type: OTHER
Group type: OTHER
Intervention: Label with neutral statements about vaping
Description: Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
Study: NCT04982796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: See description of psilocybin-enhanced psychotherapy arm.
Study: NCT04982796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Description: See description of treatment-as-usual arm.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual
Description: See description of treatment-as-usual arm.
Study: NCT05677633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
Study: NCT05746325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Photography
Description: Digital photographs taken of array placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05024084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane
Description: Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane
Description: Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
Study: NCT04955288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic balloon assisted resuscitation
Description: On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cardiopulmonary resuscitation
Description: Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal cooling
Description: The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cooling
Description: The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
Study: NCT05746325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Transducer arrays applied and wear NovoTTF-200T
Study: NCT05245903

Intervention type: DEVICE
Intervention: Emerald Device Monitoring
Description: The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
Study: NCT06041919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: Nitric Oxide agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: Nitric Oxide agent
Study: NCT04873024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cMAP Flow V 2.0
Description: Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cMAP Flow V 2.0
Description: Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment.
Study: NCT05181345

Intervention type: OTHER
Intervention: Sleep recording (at home)
Description: Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.

Intervention type: OTHER
Intervention: Sleep recording (at home)
Description: Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
Study: NCT06041919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: Nitric Oxide agent
Study: NCT05867316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: Unified Protocol based treatment, modified for use in brief treatment on inpatient units
Study: NCT05882890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranio sacral therapy
Description: Manual treatment of 5 grams on the whole airwaysystem, the throat, the neck, the meninges, the craniel , nerve sleeves, the visceral cranium, the soft tissue in the mouth
Study: NCT06041919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: Nitric Oxide agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRZE
Description: isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)